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Abstract
Synthesis, radioligand binding and molecular modeling studies of several 9-aminomethyl-9,10-
dihydroanthracene (AMDA) analogs were carried out to determine the extent of the steric
tolerance associated with expansion of the tricyclic ring system and amine substitution at 5-HT2A
and H1 receptors. A mixture of (7,12-dihydrotetraphene-12-yl)methanamine and (6,11-
dihydrotetracene-11-yl)methanamine in a 75% to 25% ratio was found to have an apparent Ki of
10 nM at the 5-HT2A receptor. A substantial binding affinity for (7,12-dihydrotetraphene-3-
methoxy-12-yl)methanamine at the 5-HT2A receptor (Ki = 21 nM) was also observed.
Interestingly, this compound was found to have 100-fold selectivity for 5-HT2A over the H1
receptor (Ki = 2500 nM). N-Phenylalkyl-AMDA derivatives, in which the length of the alkyl chain
varied from methylene to n-butylene, were found to have only weak affinity for both 5-HT2A and
H1 receptors (Ki = 223 to 964 nM). Our results show that large rigid annulated AMDA analogs
can be sterically accommodated within the proposed 5-HT2A binding site.
Over the past few years, much information has been generated about 5-HT2 receptor
subtypes (5-HT2A, 5-HT2B, 5-HT2C) and their ligands.1,2 However, it is still not clear
exactly how serotonergic ligands (agonists/partial agonists/antagonists/inverse agonists)
including 5-HT itself interact with the receptors. In the absence of a crystal structure for any
member of the 5-HT2 receptor family, homology models generated from a representative
GPCR such as rhodopsin or a β-adrenoceptor are used to study possible drug-receptor
interactions.3-5 Homology modeling and ligand docking, supported by experimental data,
have allowed us to propose possible ligand-receptor interactions responsible for the
observed affinity of the lead compound 9-aminomethyl-9,10-dihydroanthracene (AMDA)
and its analogues at the human 5-HT2A and H1 receptors.6-10 This work expands upon these
earlier structure-affinity relationship studies via new AMDA analogs designed to probe the
stereoelectronic accessibility of the receptor binding sites. In particular, annulated analogs of
AMDA were synthesized and tested to determine the extent of bulk tolerance within the
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binding site of both 5-HT2A and H1 receptors. Further, to explore the potential differences
between the 5-HT2A and H1 receptors in the vicinity of the ammonium ion binding site
(known to be D3.32 based on experimental and modeling data),11,12 N-phenylalkyl analogues
of AMDA were synthesized and tested.
The concept of using annulated analogues of established ligands as dimensional probes for
ligand binding sites has been reported but not widely employed. Examples where this
concept has been successfully applied include analogs of adenosine13, ATP14,
cyclophosphamide15, isotryptamine16 and allocolchicinoids.17 By carrying out a systematic
annulation and substitution, one can infer information about the dimensions as well as the
interactions within the binding site.18,19 AMDA and its analogues contain a rigid tricyclic
scaffold. Previous SAR studies by Westkaemper et al.5,7 using the 5-HT2A receptor have
indicated that there may be a substantial amount of steric tolerance around the rigid tricyclic
scaffold of AMDA, as determined by substituent effects at the C3-position. However, the
largest substituents examined to date (3-phenylpropyl-AMDA, Ki = 3.2 nM; 3-n-hexyl-
AMDA, Ki = 7 nM; 3-n-pentyloxy-AMDA, Ki = 23 nM)7 have a high degree of rotational
freedom due to alkyl chain flexibility. There are currently no known 5-HT2A ligands whose
rigid core exceeds the dimensions of the annulated AMDA analogs reported here. For
example, in the case of tricyclic antidepressants, ergot alkaloids and apomorphine the
longest dimension is equivalent to three linearly fused rings. As a more stringent test of bulk
tolerance, rigid and elongated structures were constructed by addition of fused rings to the
tricyclic structure of AMDA. If accommodated, the AMDA pharmacophore expanded via
benzfusion would also provide a new rigid scaffold for the introduction of substituents that
may have access to additional binding site residues more distant from the tricyclic core than
those accessible with previously-employed scaffolds.
The initial compounds for which syntheses were attempted were dihydrotetracenes (1a and
1b, Table 1). However, the synthetic methodology chosen for 1a (Scheme 1) resulted in a
mixture (75:25) of positional isomers of dihydrotetraphene 2a and dihydrotetracene 1a
respectively. In retrospect this is consistent with the greater stability of the intermediate
carbocation formed as a result of electrophilic addition at the α-carbon versus the β-carbon
of the naphthalene ring, giving rise to the kinetically-favored α-substituted product. The
binding affinity data obtained for this mixture produced an apparent Ki value of 10 nM (5-
HT2A). Thus it was concluded that at least one of the isomers would be predicted to bind
with Ki ≤ 10 nM. The annulated methoxy-analogue 1b was also synthesized using a similar
procedure. The attempted synthesis also resulted in a mixture of two isomers (1b and 2b).
Due to the challenges faced in the final cyclization step and difficulty in the separation of
products, the reaction resulted in a very low yield of the final products. While a mixture was
obtained, it was possible to separate the methoxy-substituted isomers, although only
dihydrotetraphene isomer 2b was obtained preparatively. Dihydrotetraphene 2b was
determined to have substantial affinity for the 5-HT2A receptor (Ki = 21 nM) while
possessing very low affinity for the H1 receptor (Ki = 2500 nM).
In order to explore potential differences between the 5-HT2A and H1 receptor binding sites
in the vicinity of the ligand ammonium ion, various phenylalkylamine analogs of AMDA
(3a-d) were synthesized and tested. It has previously been shown10 that increasing either the
length of the alkyl linker connecting the dihydroanthracene core to the amine or the degree
of N-methylation progressively increases the affinity of AMDA analogs for H1, but not for
5-HT2A. The binding affinity of the larger N-benzyl-AMDA (3a) has also been reported9
and shown to have a Ki value of 721 nM for the 5-HT2A receptor, dramatically lower than
for the parent compound AMDA (Ki = 20 nM). In order to further investigate the possibility
that the ligand N-substituent may interact with more remote hydrophobic regions of the
receptor in a manner similar to what has been proposed7 for 3-phenylpropyl AMDA,
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analogs 3b-d containing longer flexible linkers between the amine and the phenyl ring were
synthesized and tested. The observed affinity data showed that each of the compounds 3b-d
had relatively low affinity (Ki = 223 to 964 nM) for both 5-HT2A and H1 receptors with
practically no selectivity, indicating that the larger phenylalkylamine substituents are not
sterically well-tolerated in either receptor.
In order to provide potential insights into how the benz-fused ligands interact with their
receptors at an atomic level, automated ligand docking was carried out using an existing 5-
HT2A homology model, the construction and refinement of which has previously been
described in detail.6,7 This process is briefly described here. The initial step consisted of
sequence alignment of the h5-HT2A (P28233) sequence with several related class A
GPCRs20 using the CLUSTALX program.21 This produced an unambiguous alignment in
the transmembrane (TM) helical regions of h5-HT2A sequences with that of both bovine
rhodopsin and the β2-adrenoceptor. This alignment, along with a file containing the atomic
coordinates of the template receptor (PDB ID = 1U19), was used as input to the
MODELLER software package22 to generate a population of 100 different h5-HT2A
homology models. Each of these receptors was subsequently energy-minimized. The
automated docking program GOLD version 3.01 (Cambridge Crystallographic Data Centre,
Cambridge, UK)23 was then used to dock selected ligands into the 5-HT2A populations.
Based on the fitness function values, steric and electronic interactions of the docked poses
and reported site-directed mutagenesis data, one receptor model was selected to represent
the AMDA-antagonist binding site of the h5-HT2A receptor. This model was subsequently
analyzed using PROCHECK and the ProTable facility within SYBYL to assess the geometric
integrity of various structural elements (bond lengths, torsion angles, etc.) within the
receptor. The target compounds with explicit consideration of stereoisomers were built and
energy-minimized. These structures were docked into the receptor binding site using GOLD
as previously described.7 Visual inspection of the docked poses in conjunction with the
ChemScore fitness function was used to select the final solution for each isomer. The GOLD
program was able to place the 5-HT2A ligands 2a and 2b in the previously-predicted
AMDA-antagonist binding site (Figure 1).
In each solution, the ligand ammonium ion interacts with the D1553.32 residue in the binding
site. Compound 2a, with its extended aromatic structure, exhibited extensive lipophilic
interactions with residues surrounding the dihydrotetraphene core (Figures 1a and 1b). The
region of the binding site occupied by the dihydrotetraphene core is the same as that
previously proposed6 for the dihydroanthracene core of 3-methoxy-AMDA. Like the
stereoisomers of 3-methoxy-AMDA, the additional methoxy group of (R)-2b or (S)-2b may
be accommodated in the binding pocket through a slight shift in the position of the
polycyclic core, while the methoxy group may act as an H-bond acceptor for serine residues
S1593.36 or S771.35/S1312.61 respectively (Figures 1c and 1d). The observation that the
methoxy-substituted compound 2b showed substantial affinity (Ki = 21 nM) suggests that
the non-linear dihydrotetraphene analog 2a is a significant contributor to the observed
affinity of the 2a:1a mixture at 5-HT2A. Our homology modeling and docking studies,
however, indicate that the dihydrotetracenes 1a and 1b may also be accommodated in, and
have substantial affinity for, the proposed binding site in a manner analogous to that of the
dihydrotetraphenes 2a and 2b (ChemScores: (R)-1a, 40.75; (S)-1a, 38.23; (R)-1b, 36.49;
(S)-1b, 40.65; (R)-2a, 38.28; (S)-2a, 40.03; (R)-2b, 41.15; (S)-2b, 38.05).
The target compounds were synthesized as shown in Schemes 1 and 2. In the case of the
annulated analogs (Scheme 1), commercially available α-bromo-o-tolunitrile 4, on treatment
with DIBAL-H in anhydrous CH2Cl2 and work up using aqueous HBr, gave the aldehyde 5
in quantitative yields.24 Palladium-catalyzed cross-coupling of 2-naphthylboronic acid or 6-
methoxy-2-naphthylboronic acid with the halide 5 gave the coupled aldehydes 6a and 6b.
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Cyanosilylation of the aldehydes 6a and 6b using TMSCN gave the cyano trimethylsilyl
ether as intermediates, which were reduced with LAH to give the respective amino alcohols
7a and 7b. Cyclodehydration of amino alcohols using methanesulfonic acid gave both the
isomers of cyclized products 1a and 1b, and 2a and 2b, respectively. The synthesis of 9-(N-
benzylaminomethyl)-9,10-dihydroanthracene (3a) was reported previously.9 The
phenylalkylamines 3b-d were prepared by reduction (BH3·THF) of amides obtained by the
treatment of acid chloride with phenylethyl-, phenylpropyl- and phenylbutylamine,
respectively (Scheme 2).
Binding assays and data analysis were performed through the NIMH Psychoactive Drug
Screening Program (PDSP) using cloned human receptors. The 5-HT2A competitive binding
assay employs [3H]ketanserin (a 5-HT2A antagonist) as the radioligand, and the H1
competitive binding assay employs [3H]pyrilamine (an H1 antagonist) as the radioligand.
Binding data were analyzed using PRISM (GraphPad Software, Inc., San Diego, CA).
Details of the binding assay protocol may be found at the PDSP home page,
http://pdsp.med.unc.edu.
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Proposed binding mode of isomers of annulated AMDA analogs a) (R)-2a, b) (S)-2a, c)
(R)-2b and d) (S)-2b within the binding site of the 5-HT2A receptor. Residues within 4 Å of
the bound ligands are displayed. Hydrogen bonds are shown in magenta with donor-acceptor
distances in Ångströms.
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Reagents and conditions: (a) DIBAL-H, CH2Cl2; (b) Pd(PPh3)4, K3PO4, 2-naphthylboronic
acid/6-methoxy-2-naphthylboronic acid; (c) TMSCN, ZnI, CH2Cl2, LAH, THF; (d)
CH3SO3H.
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Reagents and conditions: (a) SOCl2, benzene; (b) phenylethylamine, phenylpropylamine or
phenylbutylamine; (c) BH3·THF.
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Table 1
Observed binding affinity data for 6,11-dihydrotetracene (1a and 1b), 7,12-dihydrotetraphene (2a and 2b) and
9,10-dihydroanthracene (3a-d) structural probes at 5-HT2A and H1 receptors.
Ki, nM (±SD)a
Cpd. R 5-HT2A H1
1a+2a −H 10 (±1)b ND
1b −OCH3 ND ND
2b −OCH3 21 (±1) 2640 (±528)
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Ki, nM (±SD)a
Cpd. R 5-HT2A H1
3a −CH2C6H5 721 (±223)c ND
3b −(CH2)2C6H5 400 (±34) 242 (±27)
3c −(CH2)3C6H5 223 (±5) 725 (±128)
3d −(CH2)4C6H5 365 (±17) 964 (±148)
a
[3H]Ketanserin-labeled cloned h5-HT2A or [3H]pyrilamine-labeled cloned hH1 sites. Values represent the mean of computer-derived Ki
estimates (using GraphPad PRISM) of multiple determinations. ND = not determined.
b
Represents a mixture (75:25) of 2a and 1a. See text for details.
c
From Runyon, et al. 2001.9
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